Serum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Study

UDC.coleccionInvestigaciónes_ES
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicases_ES
UDC.endPage1859es_ES
UDC.grupoInvEnfermidades Cerebrovasculares: Neuroloxía Clínica e Traslacional (INIBIC)es_ES
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruñaes_ES
UDC.issue6es_ES
UDC.journalTitleStrokees_ES
UDC.startPage1855es_ES
UDC.volume38es_ES
dc.contributor.authorCastellanos, María del Mar
dc.contributor.authorSobrino, Tomás
dc.contributor.authorMillán, Mónica
dc.contributor.authorGarcía, María M.
dc.contributor.authorArenillas, Juan
dc.contributor.authorNombela, Florentino
dc.contributor.authorBrea, David
dc.contributor.authorPérez de la Ossa, Natalia
dc.contributor.authorSerena, Joaquín
dc.contributor.authorVivancos, José
dc.contributor.authorCastillo, José
dc.contributor.authorDávalos, Antoni
dc.date.accessioned2025-01-20T07:24:37Z
dc.date.embargoEndDate9999-12-31es_ES
dc.date.embargoLift9999-12-31
dc.date.issued2007-05-03
dc.descriptionComparative studyes_ES
dc.description.abstract[Abstract] Background and purpose: Plasma levels of cellular fibronectin (c-Fn) > or =3.6 microg/mL and of matrix metalloproteinase-9 (MMP-9) > or =140 ng/mL have been associated with parenchymal hematoma (PH) after treatment with tissue-type plasminogen activator (t-PA) in patients with acute ischemic stroke. In this prospective study, we sought to validate the predictive capacity of the preestablished cutoff values of these biomarkers for PH in a larger series of patients. Methods: We studied 134 patients treated with t-PA within 3 hours from symptom onset according to the SITS-MOST criteria (median time to infusion, 152 minutes; median National Institutes of Health Stroke Scale score, 14) in 4 university hospitals. Hemorrhagic transformation was classified according to the European-Australasian Acute Stroke Study II definitions on computed tomography scans performed 24 to 36 hours after treatment. Relevant hemorrhagic transformation was defined as hemorrhagic infarction type 2 or any PH. Serum c-Fn and MMP-9 levels were determined by an ELISA om blood samples obtained before treatment. Results: Cranial computed tomography showed hemorrhagic transformation in 27 patients (20%), hemorrhagic infarction in 15 (type 2 in 8 patients), and PH in 12 patients (symptomatic in 4). Serum c-Fn and MMP-9 concentrations at baseline were significantly higher in patients with relevant hemorrhagic transformation and PH than in those without (all P<0.001). The sensitivity, specificity, and positive and negative predictive values for PH by c-Fn levels > or =3.6 microg/mL were 100%, 60%, 20%, and 100%, respectively, whereas corresponding values were 92%, 74%, 26%, and 99% for MMP-9 levels > or =140 ng/mL. When both biomarkers were at levels above the cutoff points, specificity increased to 87% and the positive predictive value increased to 41%. Conclusions: This prospective study confirmed the high sensitivity and negative predictive value, with retained good specificity, of c-Fn and MMP-9 for the prediction of PH in patients treated with t-PA. Development of faster analytic methods will prove the applicability of these biomarkers in routine clinical practice.es_ES
dc.description.sponsorshipThis project was partially supported by a grant from the Spanish Ministry of Health (Instituto de Salud Carlos III) and by the RETICS-RD06/0026.es_ES
dc.identifier.citationCastellanos M, Sobrino T, Millán M, García M, Arenillas J, Nombela F, Brea D, Perez de la Ossa N, Serena J, Vivancos J, Castillo J, Dávalos A. Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke. 2007 Jun;38(6):1855-9.es_ES
dc.identifier.doi10.1161/STROKEAHA.106.481556
dc.identifier.issn0039-2499
dc.identifier.urihttp://hdl.handle.net/2183/40772
dc.language.isoenges_ES
dc.publisherAmerican Heart Associationes_ES
dc.relation.urihttps://doi.org/10.1161/strokeaha.106.481556es_ES
dc.rights.accessRightsembargoed accesses_ES
dc.subjectStrokees_ES
dc.subjectHemorrhagees_ES
dc.subjectThrombolytic therapyes_ES
dc.subjectMetalloproteinaseses_ES
dc.subjectBiomarkerses_ES
dc.subjectBlood-brain barrieres_ES
dc.titleSerum Cellular Fibronectin and Matrix Metalloproteinase-9 as Screening Biomarkers for the Prediction of Parenchymal Hematoma After Thrombolytic Therapy in Acute Ischemic Stroke: A Multicenter Confirmatory Studyes_ES
dc.typejournal articlees_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationfea87394-0be5-482f-b650-543f2240258c
relation.isAuthorOfPublication.latestForDiscoveryfea87394-0be5-482f-b650-543f2240258c

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Castellanos_Serum_2007.pdf
Size:
187.92 KB
Format:
Adobe Portable Document Format
Description: